Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
91090 trials found · Page 125 of 4555
-
New breathing strategy aims to save ARDS patients by giving lungs a rest
Disease control Not yet recruitingAcute respiratory distress syndrome (ARDS) accounts for approximately 10% of all ICU admissions and 23% of patients requiring mechanical ventilation (MV). Despite advances in care, hospital mortality remains high, ranging from 34% in mild cases to 46% in severe ARDS. Positive-pre…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
Engineered immune cells take on deadliest lung cancer
Disease control Not yet recruitingBackground: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that develops anywhere other than the lungs. EPNEC is also deadly. B7-H3 is a protein often found in SCLC and EPNEC tumor cell…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 13:33 UTC
-
New hope for advanced breast cancer: phase 3 trial compares novel combo to standard care
Disease control Not yet recruitingThe purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone rece…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
New vaccine aims to stop lung cancer recurrence in High-Risk patients
⭐️ VACCINE ⭐️ TerminatedBackground: Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return. Radiation and chemotherapy can improve survival in some people who have had surgery for NSCLC, but these treatments also caus…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ VACCINE ⭐️
Last updated May 07, 2026 13:32 UTC
-
New hope for rare thyroid cancer: targeted radiation trial launches
Disease control Not yet recruitingBackground: Oncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells. Objective: To test a radioactive drug (177LuDOTA-EB-TA…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated May 07, 2026 13:32 UTC
-
New drug duo aims to wipe out lung tumors before surgery
Disease control Not yet recruitingThis is a single-center, single-arm, phase 2 trial evaluating the efficacy and safety of retlirafusp alfa combined with single-agent chemotherapy as neoadjuvant treatment for patients with resectable stage II-III EGFR/ALK wild-type non-small cell lung cancer (NSCLC).Eligible pati…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Inhaled drug mist could boost lung cancer treatment before surgery
Disease control Recruiting nowBackground: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surgery to remove the tumors is the standard treatment for people diagnosed with early stages of NSCLC. Despite complete rem…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:00 UTC
-
Blood filter shows promise for sudden liver failure patients
Disease control Not yet recruitingAcute-on-chronic liver failure (ACLF) is a serious condition in which patients with chronic liver disease suddenly develop severe liver injury, leading to inflammation, organ failure, and very high short-term mortality. Standard medical treatment can help, but many patients still…
Phase: NA • Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New immune cell therapy targets Hard-to-Treat blood cancer
Disease control Not yet recruitingThis study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with relapsed and refractory Multiple Myeloma.
Phase: PHASE1, PHASE2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New drug duo aims to shrink inoperable lung tumors enough for surgery
Disease control Not yet recruitingThis study is a phase 2 open-label, single-center clinical study to evaluate the efficacy and safety SKB264 in combination with toripalimab in patients with unresectable stage III non-small cell lung cancer
Phase: PHASE2 • Sponsor: Hunan Province Tumor Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New drug aims to reduce bleeding episodes in hemophilia patients
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without inhibitors. The study will include peop…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New Triple-Threat attack on Tough-to-Treat lung cancer
Disease control Not yet recruitingThis study is open to adults with a type of lung cancer called HER2-mutant non-squamous non-small cell lung cancer (NSCLC) that is advanced or has spread. People who have a tumor with a HER2 mutation and have not received previous treatment for their lung cancer can participate i…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 09, 2026 19:34 UTC
-
New drug combo aims to improve survival in aggressive nose cancer
Disease control Not yet recruitingThe investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk locoregionally advanced nasopharyngeal carcinoma (stage I…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
Immune cells from your own tumor could fight advanced cancer
Disease control Not yet recruitingThis study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatmen…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New vaccine aims to shield transplant patients from deadly virus
Prevention Recruiting nowThis phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Hapl…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated May 04, 2026 16:17 UTC
-
New drug trial offers hope for rare blood cancers
Disease control Recruiting nowBackground: Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorders that can cause serious complications in children and adults. MDS and MDS/MPN can also progress to acute myeloid leukemia. Treatments for these disorders are r…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
New hope for Tough-to-Treat colon cancer: phase 3 trial launches
Disease control Not yet recruitingColorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine a…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 04, 2026 16:24 UTC
-
New immunotherapy MK-1045 targets Hard-to-Treat lymphomas
Disease control Not yet recruitingResearchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that cause…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 06, 2026 16:04 UTC
-
New drug targets deadly brain cancer that has returned
Disease control Not yet recruitingBackground: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells. Objective: …
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
New cream shows promise for chronic skin condition
Disease control Not yet recruitingThe main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because …
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated May 05, 2026 11:55 UTC